Remote Assessment of Cognitive Function Feasible With Hematologic Malignancies
Researchers demonstrated the feasibility of remote cognitive assessments in patients with hematologic malignancies.
Non-Hodgkin Lymphoma
Epcoritamab Granted Priority Review for Relapsed/Refractory Large B-Cell Lymphoma
Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.
Atezolizumab Does Not Improve PFS in Previously Untreated Follicular Lymphoma
Adding atezolizumab to obinutuzumab and bendamustine does not improve progression-free survival and carries an increased risk of adverse events, a study suggests.
Consolidative Stem Cell Transplant May Improve Outcomes in PTCL
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Atezolizumab Plus R-CHOP Deemed Unworthy of Additional Study in Diffuse Large B-Cell Lymphoma
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
Outcomes After BTK Inhibitor Failure in Rel/Ref Mantle Cell Lymphoma
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Tucidinostat Deemed Promising in Relapsed/Refractory Peripheral T-Cell Lymphoma
Tucidinostat appears safe and effective in patients with relapsed/refractory peripheral T-cell lymphoma.
Ultra-Low-Dose Radiation Appears Effective in Orbital Indolent B-Cell Lymphoma
Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.
Orelabrutinib Plus R-CHOP Appears Active in Extranodal, Non-GCB DLBCL
The aim of this trial was to evaluate the efficacy and safety of orelabrutinib plus R-CHOP in patients with extranodal non-GCB DLBCL.
Cutaneous T-Cell Lymphoma Incidence on the Rise in the United States
The incidence of cutaneous T-cell lymphoma in the United States increased from 2000 to 2018, with an annual percent change of 0.61%.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...